Skip to content

Clinical trials

Terminated Multiple Myeloma trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Multiple Myeloma Phase: Not applicable Status: Terminated Clear all

41 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20022
20031
20041
20052
20072
20081
20091
20102
20123
20133
20144
20151
20161
20171
20181
20191
20204
20213
20221
20232
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Terminated41

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Masonic Cancer Center, University of Minnesota4
M.D. Anderson Cancer Center3
Nantes University Hospital2
Wake Forest University Health Sciences2
Albert Einstein College of Medicine1
Assistance Publique - Hôpitaux de Paris1
Centre Hospitalier Henri Duffaut - Avignon1
Centre Hospitalier Universitaire, Amiens1
City of Hope Medical Center1
European Organisation for Research and Treatment of Cancer - EORTC1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Multiple Myeloma41
Precursor Cell Lymphoblastic Leukemia-Lymphoma15
Hodgkin Disease14
Leukemia, Lymphocytic, Chronic, B-Cell14
Lymphoma, Non-Hodgkin14
Leukemia, Myeloid, Acute13
Lymphoma, Mantle-Cell13
Burkitt Lymphoma11
Leukemia11
Lymphoma, B-Cell, Marginal Zone11

Trials

Showing 1 to 25 of 41. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.